- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund ; day:24 ; month:4 ; year:2024 ; pages:1-5
Gene therapy ; (24.4.2024), 1-5
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41434-024-00452-2
- URN
-
urn:nbn:de:101:1-2407090943398.296027048394
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Risse, Johanna
- Krzemien, Merlin
- Schnalke, Jan
- Heinemann, Thomas
- SpringerLink (Online service)
Ähnliche Objekte (12)
Variables affecting pricing of orphan drugs: the Italian case
African Orphan Crops Consortium (AOCC): status of developing genomic resources for African orphan crops
Genomic technologies—from tools to therapies
Pricing and reimbursement of orphan drugs: the need for more transparency
Shining a light in the black box of orphan drug pricing
Ethical considerations in prenatal genomic testing
Pricing sin stocks: Ethical preference vs. risk aversion
Pricing sin stocks: Ethical preference vs. risk aversion
Pricing Sin Stocks: Ethical Preference vs. Risk Aversion
Progressive Pricing: The Ethical Case for Price Personalization
Pricing sin stocks : ethical preference vs. risk aversion
Application of four pricing models for orphan medicines: a case study for lumasiran
Variables affecting pricing of orphan drugs: the Italian case
African Orphan Crops Consortium (AOCC): status of developing genomic resources for African orphan crops
Genomic technologies—from tools to therapies
Pricing and reimbursement of orphan drugs: the need for more transparency
Shining a light in the black box of orphan drug pricing
Ethical considerations in prenatal genomic testing
Pricing sin stocks: Ethical preference vs. risk aversion
Pricing sin stocks: Ethical preference vs. risk aversion
Pricing Sin Stocks: Ethical Preference vs. Risk Aversion
Progressive Pricing: The Ethical Case for Price Personalization
Pricing sin stocks : ethical preference vs. risk aversion
Application of four pricing models for orphan medicines: a case study for lumasiran
Variables affecting pricing of orphan drugs: the Italian case
African Orphan Crops Consortium (AOCC): status of developing genomic resources for African orphan crops
Genomic technologies—from tools to therapies
Pricing and reimbursement of orphan drugs: the need for more transparency
Shining a light in the black box of orphan drug pricing
Ethical considerations in prenatal genomic testing
Pricing sin stocks: Ethical preference vs. risk aversion
Pricing sin stocks: Ethical preference vs. risk aversion
Pricing Sin Stocks: Ethical Preference vs. Risk Aversion
Progressive Pricing: The Ethical Case for Price Personalization
Pricing sin stocks : ethical preference vs. risk aversion